(Q41120664)

27 September 2017

1 reference

title

Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia (English)

1 reference

27 September 2017

1 reference

C J Dunn

1

1 reference

27 September 2017

K L Goa

series ordinal

2

1 reference

27 September 2017

language of work or name

1 reference

1 August 1996

1 reference

27 September 2017

1 reference

27 September 2017

9

1 reference

27 September 2017

122-147

1 reference

27 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199609020-00007

27 September 2017

0 references

cites work

Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia

1 reference

12 December 2020

Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia

1 reference

12 December 2020

Therapeutic activity of mitoxantrone and ametantrone against murine tumors

1 reference

12 December 2020

High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study

1 reference

12 December 2020

Unusual side effect of mitoxantrone

1 reference

12 December 2020

Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia

1 reference

12 December 2020

DNA topoisomerase-trapping antitumour drugs

1 reference

12 December 2020

A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.

1 reference

12 December 2020

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

1 reference

12 December 2020

Disposition of mitoxantrone in cancer patients

1 reference

12 December 2020

Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia

1 reference

12 December 2020

New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites

1 reference

12 December 2020

Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone

1 reference

12 December 2020

Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture.

1 reference

12 December 2020

Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.

1 reference

12 December 2020

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group

1 reference

12 December 2020

Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

1 reference

12 December 2020

DNA topoisomerase poisons as antitumor drugs

1 reference

12 December 2020

Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone

1 reference

12 December 2020

Acute myelogenous leukemia in the older patient.

1 reference

12 December 2020

Induction of DNA strand breaks associated with apoptosis during treatment of leukemias.

1 reference

12 December 2020

A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia

1 reference

12 December 2020

Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.

1 reference

12 December 2020

Cytotoxic-drug extravasation

1 reference

12 December 2020

Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin

1 reference

12 December 2020

Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.

1 reference

12 December 2020

Identification of human urinary mitoxantrone metabolites

1 reference

12 December 2020

Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence

1 reference

12 December 2020

Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.

1 reference

12 December 2020

Acute myeloid leukaemia in the elderly: biology and treatment

1 reference

12 December 2020

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia

1 reference

12 December 2020

Acute leukemia in adults: recent developments in diagnosis and treatment.

1 reference

12 December 2020

Mitoxantrone in the treatment of acute leukemia

1 reference

12 December 2020

Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors

1 reference

12 December 2020

Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone

1 reference

12 December 2020

MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia

1 reference

12 December 2020

Acute myelogenous leukemia: current treatment and future directions.

1 reference

12 December 2020

Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy

1 reference

12 December 2020

Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia.

1 reference

12 December 2020

Clinical safety and tolerance of mitoxantrone

1 reference

12 December 2020

Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells

1 reference

12 December 2020

Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia

1 reference

12 December 2020

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.

1 reference

12 December 2020

Plasma kinetics of mitoxantrone in leukemic patients

1 reference

12 December 2020

Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON)

1 reference

12 December 2020

Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia

1 reference

12 December 2020

Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia

1 reference

12 December 2020

Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia

1 reference

12 December 2020

Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy

1 reference

12 December 2020

The clinical pharmacology of mitozantrone

1 reference

12 December 2020

Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.

1 reference

12 December 2020

Treatment of adult acute leukemia

1 reference

12 December 2020

Clinical pharmacology of mitoxantrone.

1 reference

12 December 2020

Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia

1 reference

12 December 2020

Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia

1 reference

12 December 2020

Pharmacokinetics and metabolism of mitoxantrone. A review

1 reference

12 December 2020

A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia

1 reference

12 December 2020

High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults

1 reference

12 December 2020

Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.

1 reference

12 December 2020

Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review

1 reference

12 December 2020

Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.

1 reference

12 December 2020

Membrane transport of mitoxantrone by L1210 leukemia cells

1 reference

12 December 2020

Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).

1 reference

12 December 2020

DNA topoisomerases: why so many?

1 reference

12 December 2020

Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival

1 reference

12 December 2020

Treatment of acute myelogenous leukemia in the elderly

1 reference

12 December 2020

Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia

1 reference

12 December 2020

High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells

1 reference

12 December 2020

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Mitoxantrone: an overview of safety and toxicity

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

1 reference

12 December 2020

Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.

1 reference

12 December 2020

Human autopsy tissue concentrations of mitoxantrone.

1 reference

12 December 2020

Mitoxantrone for refractory and relapsed acute leukemia

1 reference

12 December 2020

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

1 reference

12 December 2020

Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line

1 reference

12 December 2020

Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone

1 reference

12 December 2020

Mitoxantrone and etoposide in breast milk

1 reference

12 December 2020

Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia

1 reference

12 December 2020

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia

1 reference

12 December 2020

Differential alteration of cellular lipids in drug sensitive and resistant P388 leukemia cells by clofibrate: effects on mitoxantrone cytotoxicity.

1 reference

12 December 2020

1 reference

12 December 2020

Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil

1 reference

12 December 2020

Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.

1 reference

12 December 2020

Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias

1 reference

12 December 2020

Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia

1 reference

12 December 2020

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

12 December 2020

Inhibitory Effect of Mitoxantrone on Activity of Protein Kinase C and Growth of HL60 Cells1

1 reference

12 December 2020

In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML)

1 reference

12 December 2020

Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study

1 reference

12 December 2020

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison

1 reference

12 December 2020

Effect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute Leukemia

1 reference

12 December 2020

1 reference

12 December 2020

DNA strand breakage by peroxidase-activated mitoxantrone

1 reference

12 December 2020

Rationale for the use of mitoxantrone in the older patient: cardiac toxicity.

1 reference

12 December 2020

Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia

1 reference

12 December 2020

Mitoxantrone extravasation injury

1 reference

12 December 2020

Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia

1 reference

12 December 2020

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

12 December 2020

In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells.

1 reference

12 December 2020

Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.

1 reference

12 December 2020

1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation.

1 reference

12 December 2020

Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.

1 reference

12 December 2020

Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.

1 reference

12 December 2020

Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia

1 reference

12 December 2020

Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones

1 reference

12 December 2020

Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukemia cells with multidrug resistance

1 reference

12 December 2020

Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia

1 reference

12 December 2020

10.2165/00002512-199609020-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

27 September 2017

0 references

1 reference